Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH

December 11, 2023

https://www.globenewswire.com/news-release/2023/12/11/2793942/0/en/Biomea-Fusion-Presents-Achievement-of-Minimal-Residual-Disease-Negativity-MRD-neg-in-First-Complete-Responder-from-Ongoing-Phase-I-Study-COVALENT-101-of-BMF-219-in-Patients-with-Re.html

REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, presented positive clinical data for BMF-219, an investigational covalent menin inhibitor, in relapsed / refractory AML patients with menin-dependent mutations at the 65th American Society of Hematology (ASH) Annual Meeting. The poster can be viewed at Biomea’s website at https://biomeafusion.com/publications.

Read more at globenewswire.com

Related news for (BMEA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.